What is Hasumi vaccine?
The Hasumi vaccine was developed in 1948 by the late Dr. Kiichiro Hasumi based on the cancer virus theory. 17 years before the development, cancer caused by a virus was discovered in mammals in 1931, and we came up with the virus theory for human cancer and started
research on cancer vaccines. Regardless of whether the virus takes the form of infection to humans or is already integrated into a normal gene and is expressed as a trait in the wake of it, cancer causes normal cells on the surface of the cell membrane. I predicted that there is no specific antigen.
Therefore, we thought that it would be possible to treat cancer by extracting a specific antigen from the cell membrane of the cancer and administering it together with an adjuvant (immunostimulant).
Its main function is to normalize the function of diminished lymphocytes. In
addition, an adjuvant (immunostimulant) is responsible for arming lymphocytes. It recognizes cancer cells in the body as foreign substances and enhances autoimmunity to eliminate them, but it is also characterized by having few side effects. After being diagnosed with cancer, the Hasumi vaccine can be used in combination with standard treatment such as surgery, anticancer drugs, and radiation therapy to eliminate cancer while maintaining physical strength. After standard treatment, the Hasumi vaccine is used. It is a useful treatment to prevent recurrence in daily life, or to improve the life-prolonging effect and QOL (quality of life) by suppressing the progression of the condition if the condition has already progressed.
In other words, Hasumi vaccine can be used for patients with all pathological conditions from treatment to prevention. Purpose and effect of Hasumi vaccine Elimination of cancer while maintaining physical strength by using in combination with standard treatments such as surgery, chemotherapy, and radiation therapy (reduction of side effects by anticancer drugs and radiation therapy)
- Prevention of recurrence after standard treatment
- Life-prolonging effect on advanced cancer
- Improvement of QOL (quality of life: increased appetite, pain relief, improvement of
- fatigue symptoms, weight gain, etc.)
- Cancer prevention by inheritance and lifestyle
- Improved 5-year survival rate for cancer
5-year survival rate
The 5-year survival rate of cancer indicates the probability of survival 5 years after the diagnosis of cancer, and is an index showing the therapeutic effect of the facility. Comparing patients who used the Hasumi vaccine with the publicly available 5-year survival rate, there is a general 15% to 25% improvement, although it varies depending on the type of cancer.
IMMUNO CELL THERAPY
Among the immune cell therapies currently used around the world, well-known ones include NK (natural killer) cell therapy, LAK (rack) therapy, and gamma delta T cell therapy. Human immunity fights foreign substances in two stages: “innate immunity” that is innately prepared, and “adaptive immunity” that is only available to advanced life forms.
Lymphocytes, which are the linchpin of immunity, contain many immune cells such as “NK cells” and “T cells”. LAK therapy (Fig. 2) multiplies them all at once outside the body and returns them to the body, and NK cell therapy increases only NK cells and returns them (Fig. 3).
In addition, gamma-delta T cells, which contain only 2 to 3% of lymphocytes, can recognize cancer cells by various landmarks other than molecules expressed in abnormal cells such as cancer and cancer antigens (proteins that immune cells use as markers of attack). Therefore, it is possible to attack cancer cells that do not present antigens (Fig. 4).
NK cell therapy
NK cells, which contain about 10% of lymphocytes, are powerful soldiers with innate immunity. It constantly patrols the body and immediately begins to attack abnormal cells, such as tumor cells. NK cells are indispensable for the “initial immune defense line”.
NK cell culture
Since NK cells are a type of innate immunity that does not require antigens, they can attack cancer cells immediately, but since the life span of the cells themselves is short, it is effective to increase the amount of NK cells and increase the chance of contact with cancer cells.
First, 30 ml of blood is collected from the patient and NK cells contained in the blood are extracted. These cells are cultured and activated in a clean room (cell culture room) over a period of approximately 3 ~ 4 weeks.
Administration of NK cells
It is administered intravenously by intravenous drip over a period of about 30 minutes. Basically, it is administered every 2 weeks and is 6 times 1 course.
Effects of NK cell therapy
NK cell therapy is a treatment method that takes cells from the patient himself and cultures them, so it has a high affinity even after returning it to the patient, and the risk of side effects is small. When used in combination with cancer vaccines and anticancer drug treatments, it is expected to improve antitumor effects and QOL by improving immunity.
LAK Therapy
After the effective case of LAK therapy for terminal cancer was reported in the 1980s by Dr. Rosenberg of the National Institutes of Health, it has been applied to on-site treatment at the National Cancer Center and the Institute of Medical Science, the University of Tokyo. Zhuguangkai started LAK treatment in 1990. We have made numerous improvements to the culture technology.
How LAK therapy works
First, 20 ml of blood is collected from the patient, and only lymphocytes (white blood cells) are separated from it. Isolated lymphocytes are cultured for 2 weeks using IL-2 and solidified antiCD3 antibodies. Then, cells (LAK cells) that attack tumor (cancer) cells and enhance immune ability proliferate.
The mechanism of LAK therapy is to promote the destruction of cancer cells and the elimination of foreign substances by returning the LAK cells born by this culture to the patient’s body.
Administration of LAK therapy
It is administered intravenously by intravenous drip over a period of about 30 minutes. Basically, it is administered every 2 weeks and is 6 times 1 course.
Effects of LAK Therapy
For patients undergoing radiation therapy or chemotherapy, it can reduce side effects and boost immunity, while also helping to prevent cancer from recurring after surgery.
Gamma Delta T cell therapy
Gamma delta T cells are excellent lymphocytes that can attack cancer cells by a different mechanism of action than NK cells and LAK cells, but they are only afew percent present in peripheral blood.
Gamma delta T cell therapy is a treatment in which only a small number of gamma-delta T cells are multiplied outside the body and then returned to the body.
Test culture
Since there are individual differences in the sensitivity of reagents that grow gamma-delta T cells, it is necessary to conduct test culture before treatment to investigate the optimal concentration. Depending on the patient, growth may not be observed in this test culture and may be out of indication for treatment.
Culture method
First, 8 ml of blood is collected from the patient, and the concentration of zoledronic acid and CD3 reactivity are changed to test culture under 6 types of conditions.
Once the optimum concentration of the reagent is determined, 32 ml of blood is collected from the patient again, lymphocytes (white blood cells) are separated, and cultured using the optimum concentration of zoledronic acid and IL-2 for about 2 weeks.
Administration of gamma-delta T cells
It is administered intravenously by intravenous drip over a period of about 30 minutes. Basically, it is administered every 2 weeks and is 6 times 1 course.
Effects of Gamma Delta T Cell Therapy
Gamma delta T cell therapy is a treatment method that takes cells from the patient himself and cultures them, so it has a high affinity even after returning it to the patient, and the risk of side effects is low. By using it in combination with cancer vaccines and anticancer drug treatments, it is expected to improve antitumor effects and QOL by improving immunity